EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

CAR-NK cell therapy: a potential antiviral platform

Ming-Hao Lin, Li-Juan Hu, Jeffrey S Miller, Xiao-Jun Huang, Xiang-Yu Zhao

Science Bulletin · 2025

DOI: 10.1016/j.scib.2025.01.002 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Science Bulletin, 2025. Verfasst von Ming-Hao Lin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Ke…. Hauptthemen laut MEDLINE: Killer Cells, Natural, Receptors, Chimeric Antigen, Virus Diseases, Immunotherapy, Adoptive. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 157 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Beijing Natural Science Foundation, National Major Science and Technology Projects of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Viral infections persist as a significant cause of morbidity and mortality worldwide. Conventional therapeutic approaches often fall short in fully eliminating viral infections, primarily due to the emergence of drug resistance. Natural killer (NK) cells, one of the important members of the innate immune system, possess potent immunosurveillance and cytotoxic functions, thereby playing a crucial role in the host's defense against viral infections. Chimeric antigen receptor (CAR)-NK cell therapy has been developed to redirect the cytotoxic function of NK cells specifically towards virus-infected cells, further enhancing their cytotoxic efficacy. In this manuscript, we review the role of NK cells in antiviral infections and explore the mechanisms by which viruses evade immune detection. Subsequently, we focus on the optimization strategies for CAR-NK cell therapy to address existing limitations. Furthermore, we discuss significant advancements in CAR-NK cell therapy targeting viral infections, including those caused by severe acute respiratory syndrome coronavirus 2, human immunodeficiency virus, hepatitis B virus, human cytomegalovirus, and Epstein-Barr virus.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Killer Cells, NaturalReceptors, Chimeric AntigenVirus DiseasesImmunotherapy, AdoptiveHumansSARS-CoV-2COVID-19Cell- and Tissue-Based TherapyAnimals

Stichwörter der Autor:innen

CAR-NK cell therapyNK cell therapyOptimization strategiesVirus

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Pe…
  • Department of Medicine, University of Minnesota, Minneapolis, 55455, USA. Electronic address: mille011@umn.edu.

Förderung

  • National Natural Science Foundation of China
  • Beijing Natural Science Foundation
  • National Major Science and Technology Projects of China
  • Beijing Nova Program

Zitieren

APA

Lin, M. H., Hu, L. J., Miller, J. S., Huang, X. J., & Zhao, X. Y. (2025). CAR-NK cell therapy: a potential antiviral platform. Science Bulletin. https://doi.org/10.1016/j.scib.2025.01.002

Vancouver

Lin MH, Hu LJ, Miller JS, Huang XJ, Zhao XY. CAR-NK cell therapy: a potential antiviral platform. Science Bulletin. 2025. doi:10.1016/j.scib.2025.01.002

BibTeX
@article{Lin2025,
  author = {Lin, Ming-Hao and Hu, Li-Juan and Miller, Jeffrey S and Huang, Xiao-Jun and Zhao, Xiang-Yu},
  title = {CAR-NK cell therapy: a potential antiviral platform},
  journal = {Science Bulletin},
  year = {2025},
  doi = {10.1016/j.scib.2025.01.002}
}
Kostenlos starten →